Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001669
Status:
COMPLETED
Last Update Posted:
2008-03-04
First Post:
1999-11-03
Brief Title:
A 48-Week 24-Week Baseline Followed by a 24-Week Treatment Phase II Pilot Study of the Tolerability and EffectEfficacy of Subcutaneously Administered Insulin-Like Growth Factor-1 rhIGF CEP-151 in Multiple Sclerosis MS Patients
Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Organization:
National Institutes of Health Clinical Center CC
Organization Data
Organization:
National Institutes of Health Clinical Center CC
Class:
NIH
Study ID:
970148
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
National Institute of Neurological Disorders and Stroke NINDS
Lead Sponsor Class:
NIH
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None